|
|
||||||||
CLINICAL STUDY |
Departments of Endocrinology and Metabolism and 1 Cardiology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
(Correspondence should be addressed to AM Pereira, Email: A.M.Pereira{at}lumc.nl)
Introduction: This study was designed to evaluate potential reversibility of left-ventricular (LV) dysfunction in patients with acromegaly following long-term control of disease. It is unknown whether the cardiac changes induced by acromegaly can be reversed completely by long-term strict control of growth hormone excess by octreotide.
Patients and methods: We compared LV systolic and diastolic function in inactive patients with acromegaly (n = 22), who were divided into patients with long-term control by octreotide (n = 14) and patients with long-term cure by surgery/radiotherapy (n = 8). We also assessed these parameters in patients with active acromegaly (n = 17).
Results: In patients with active acromegaly, systolic function at rest was decreased by 18% (P < 0.01), LV mass index increased by 40% (P < 0.04) and isovolumetric relaxation time increased by 19% (P < 0.01), compared with patients with inactive acromegaly. These parameters were not different between well-controlled and cured patients. Using tissue Doppler imaging, the ratio between early and late diastolic velocity (E'/A' ratio) was decreased in active, compared with inactive acromegaly (0.75±0.07 versus 1.24±0.15; P < 0.01). This E'/A' ratio was considerably higher in cured, compared with octreotide-treated, patients (1.75±0.41 versus 1.05±0.1; P < 0.01).
Conclusion: Diastolic function is persistently and significantly more impaired in acromegalic patients with long-term control by octreotide than in surgically cured patients, which points to biological effects of subtle abnormalities in growth hormone secretion. Criteria for strict biochemical control of acromegaly should thus be reconsidered.
This article has been cited by other articles:
![]() |
A. A van der Klaauw, J. J Bax, G. B Bleeker, E. R Holman, V Delgado, J. W A Smit, J. A Romijn, and A. M Pereira Cardiac manifestations of GH deficiency after treatment for acromegaly: a comparison to patients with biochemical remission and controls Eur. J. Endocrinol., December 1, 2008; 159(6): 705 - 712. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. M. Dekkers, N. R. Biermasz, A. M. Pereira, J. A. Romijn, and J. P. Vandenbroucke Mortality in Acromegaly: A Metaanalysis J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 61 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Ronchi, V. Varca, P. Beck-Peccoz, E. Orsi, F. Donadio, A. Baccarelli, C. Giavoli, E. Ferrante, A. Lania, A. Spada, et al. Comparison between Six-Year Therapy with Long-Acting Somatostatin Analogs and Successful Surgery in Acromegaly: Effects on Cardiovascular Risk Factors J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 121 - 128. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |